Granite Point Capital Management’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Granite Point Capital Management’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2	Closed	-$304K	–	143
2018 Q1	$304K	Buy	+2	New	+$243K	0.03%	95

Other funds holding YARW

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Granite Point Capital Management's YARW Position: Q2 2018 in Review

Granite Point Capital Management sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q2 2018, closing a stake of 2 shares — an estimated $304K sold.

Granite Point Capital Management first reported a position in YARW in Q1 2018 and held it in 1 quarter. The position peaked at $304K in Q1 2018. 35 funds tracked by Wall St. Rank hold YARW as of Q2 2018.

Granite Point Capital Management reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Granite Point Capital Management sold 2 Yarrow Bioscience, Inc. Common Stock shares in Q2 2018, an estimated $304K.
Granite Point Capital Management first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
Granite Point Capital Management's Yarrow Bioscience, Inc. Common Stock position peaked at $304K in Q1 2018.
35 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q2 2018.

Based on Granite Point Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.